ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Unlocking the Therapeutic Potential of Integrin-Linked Kinase Inhibitors in Bioengineered 3D Breast Tumor Stroma Models.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unlocking the Therapeutic Potential of Integrin-Linked Kinase Inhibitors in Bioengineered 3D Breast Tumor Stroma Models.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The tumor microenvironment (TME) plays a pivotal role in breast cancer progression and metastasis, and the efficacy of targeted therapies is influenced by the heterogeneous nature of the TME. Interactions between breast cancer cells and their surrounding stromal cells modulate proliferation, invasion, and survival pathways, often via integrin-mediated mechanotransduction and growth factor signaling. Integrin-linked kinase (ILK) is a serine/threonine protein kinase that has been widely established as a critical driver of breast cancer progression, metastasis, and therapeutic resistance. Its expression is frequently upregulated in breast cancer tumors and correlates with poor prognosis. Given that ILK activity is highly dependent on cell-matrix interactions that are only recapitulated in 3D culture, we investigated the effect of an ILK inhibitor in 3D bioengineered compartmentalized breast tumoroid models to better mimic in vivo conditions. Two tumor cell masses (MDA-MB-231 or MCF-7) were cultured within a primary breast tissue stromal compartment representative of breast tissue or a metastatic representative of lung tissue. In highly invasive and highly hypoxic MDA-MB-231 3D tumoroid models, ILKI treatment was 2.2 fold more effective in 3D models representative of breast tissue (p-value < 0.0001) compared to those with the metastatic lung compartment (p-value = 0.03). However, ILKI treatment was slightly more effective (1.4 fold) in the less invasive and less hypoxic MCF-7 3D tumoroid models with the metastatic lung compartment compared to those with the primary breast compartment. Non-invasive imaging of oxygen gradients in the 3D models shows alleviation of hypoxia following treatment and correlation with enhanced treatment efficacy. These results emphasize the necessity of modeling both the tumor and the stroma since this interaction can directly influence drug efficacy. Moreover, ILK inhibitor treatment holds promise for breast cancer therapy particularly in chemotherapeutic resistant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.